Radium-223 behandling af knoglemetastaser ved kastrationsrefraktær prostatacancer

Research output: Contribution to journalJournal articlepeer-review

The alpha emitter Radium-223 ((22)3Ra-Cl2) is a bone-seeking radionuclide studied as a new treatment for patients with bone metastases from hormone refractory prostate cancer. More than 1,000 patients have been included in clinical phase I-III tests showing significant reduction in alkaline phosphatase- and PSA level and prolonged survival. Adverse events are usually mild to moderate and comprise gastrointestinal and myelotoxic symp-toms. Intravenously administered (22)3Ra-Cl2 (half-life 11.4 days) will likely be given every four weeks for six treatments to out-patients.

Translated title of the contributionRadium-223 treatment of bone metastases from castration-resistant prostate cancer.
Original languageDanish
JournalUgeskrift for Laeger
Issue number30
Pages (from-to)1399-1402
Number of pages4
Publication statusPublished - 21 Jul 2014

ID: 137378962